PriceTargets.com logo

Inventiva - IVA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.00
  • Forecasted Upside: 771.67%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.13 As of 03/22/2023 03:09 PM ET
▲ +0.13 (3.25%)

This chart shows the closing price for IVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inventiva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVA

Analyst Price Target is $36.00
▲ +771.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 771.67% upside from the last price of $4.13.

This chart shows the closing price for IVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Inventiva. This rating has held steady since October 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/22/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2023Stifel NicolausInitiated CoverageBuyLow
11/15/2022Societe GeneraleDowngradeBuy ➝ SellN/A
9/23/2022HC WainwrightLower TargetBuy$42.00 ➝ $36.00Low
11/22/2021HC WainwrightBoost TargetBuy$40.00 ➝ $42.00Low
9/22/2021HC WainwrightReiterated RatingBuy$38.00 ➝ $40.00Low
9/22/2021HC WainwrightBoost TargetBuy$38.00 ➝ $40.00High
5/4/2021Roth CapitalReiterated RatingBuyLow
3/15/2021Societe GeneraleReiterated RatingBuy ➝ SellHigh
3/8/2021Societe GeneraleDowngradeBuy ➝ SellMedium
1/21/2021Stifel NicolausReiterated RatingBuy$18.00Low
9/21/2020Chardan CapitalReiterated RatingNeutralLow
9/18/2020HC WainwrightReiterated RatingBuyHigh
8/17/2020HC WainwrightReiterated RatingBuy$38.00Low
8/5/2020Roth CapitalInitiated CoverageBuyMedium
8/4/2020Stifel NicolausInitiated CoverageBuy$18.00High
8/4/2020GuggenheimInitiated CoverageBuy$26.00High
(Data available from 3/22/2018 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2023

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Inventiva logo
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Read More

Today's Range

Now: $4.13
Low: $4.00
High: $4.26

50 Day Range

MA: $5.60
Low: $4.00
High: $6.53

52 Week Range

Now: $4.13
Low: $3.49
High: $12.15

Volume

3,090 shs

Average Volume

7,450 shs

Market Capitalization

$174.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Inventiva?

The following equities research analysts have issued reports on Inventiva in the last twelve months: HC Wainwright, Societe Generale, and Stifel Nicolaus.
View the latest analyst ratings for IVA.

What is the current price target for Inventiva?

1 Wall Street analysts have set twelve-month price targets for Inventiva in the last year. Their average twelve-month price target is $36.00, suggesting a possible upside of 771.7%. HC Wainwright has the highest price target set, predicting IVA will reach $36.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $36.00 for Inventiva in the next year.
View the latest price targets for IVA.

What is the current consensus analyst rating for Inventiva?

Inventiva currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IVA, but not buy more shares or sell existing shares.
View the latest ratings for IVA.

What other companies compete with Inventiva?

Other companies that are similar to Inventiva include G1 Therapeutics, ORIC Pharmaceuticals, IMARA, Greenwich LifeSciences and Merrimack Pharmaceuticals. Learn More about companies similar to Inventiva.

How do I contact Inventiva's investor relations team?

Inventiva's physical mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The company's listed phone number is 33-3-80-44-75-00 and its investor relations email address is [email protected] The official website for Inventiva is www.inventivapharma.com. Learn More about contacing Inventiva investor relations.